<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195804</url>
  </required_header>
  <id_info>
    <org_study_id>1144.3</org_study_id>
    <nct_id>NCT02195804</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers</brief_title>
  <official_title>A Phase I Open-label, Randomised, Single Dose, Three-way Crossover Relative Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) Formulations Following Oral Administration in Fasting, Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to establish the relative bioavailability (BA) of two&#xD;
      different ranitidine hydrochloride 150 mg ODT formulation in comparison to the current, over&#xD;
      the counter (OTC) ranitidine hydrochloride (Maximum Strength ZANTAC 150®) formulation&#xD;
      following oral single dose administration in fasting healthy male volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of ranitidine in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of ranitidine in plasma (Cmax)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of ranitidine in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of ranitidine in plasma (tmax)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant in plasma (λz)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of ranitidine in plasma (t1/2)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analyte in the body after po administration (MRTpo)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>up to 16 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 38 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>24 hours after drug dosing at the end of each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ranitidine HCL ODT Vanilla-Mint</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranitidine HCL ODT RM Vanilla-Mint</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranitidine HCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maximum Strength ZANTAC 150®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine hydrochloride ODT</intervention_name>
    <description>Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)</description>
    <arm_group_label>Ranitidine HCL ODT Vanilla-Mint</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine hydrochloride ODT RM</intervention_name>
    <description>Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)</description>
    <arm_group_label>Ranitidine HCL ODT RM Vanilla-Mint</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine hydrochloride</intervention_name>
    <arm_group_label>Ranitidine HCL</arm_group_label>
    <other_name>Maximum Strength ZANTAC 150®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects based on: complete medical history, including a physical&#xD;
             examination, vital signs (pulse rate (PR), systolic &amp; diastolic blood pressure (BP)&#xD;
             and body temperature), 12-lead electrocardiogram (ECG) and clinical laboratory tests&#xD;
&#xD;
          -  Age ≥ 18 and Age ≤ 60 years&#xD;
&#xD;
          -  BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index) and body weight of ≥ 55 kg&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically relevant abnormality found on the screening physical examination&#xD;
             (including BP, PR) or ECG or in the opinion of the investigator the patient is not&#xD;
             suitable for the study&#xD;
&#xD;
          -  Any evidence of an acute or chronic gastrointestinal conditions or relevant&#xD;
             concomitant medical disease&#xD;
&#xD;
          -  History of acute porphyria&#xD;
&#xD;
          -  History of peptic ulcer disease&#xD;
&#xD;
          -  Heartburn requiring treatment (OTC or prescription medicine) within the last 30 days&#xD;
&#xD;
          -  History of surgery of the gastrointestinal tract surgery (except appendectomy and&#xD;
             cholecystectomy)&#xD;
&#xD;
          -  History of relevant allergy / hypersensitivity (including allergy to H2 inhibitor) to&#xD;
             the drug class, ranitidine hydrochloride or its excipients)&#xD;
&#xD;
          -  Intake of prescription or over-the-counter (OTC) drugs with a long half-life (&gt;24&#xD;
             hours) within at least 2 weeks or less than 10 half-lives of the respective drug prior&#xD;
             to administration or during the trial&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within 30 days prior to&#xD;
             administration or during the trial&#xD;
&#xD;
          -  Inability to refrain from alcohol use 48 hours prior to drug administration until the&#xD;
             end of the study visit for each treatment period&#xD;
&#xD;
          -  History of alcohol (more than 60 g/day) or drug abuse&#xD;
&#xD;
          -  Blood donation (more than 100 mL within four weeks prior to administration or during&#xD;
             the trial)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that is of clinical relevance as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
          -  Subjects who test positive upon drug screening&#xD;
&#xD;
          -  Subjects who consume caffeine or xanthine-containing drinks or foods (coffee, tea,&#xD;
             cola, energy drinks, chocolate, etc.) 48 hours prior to study drug administration&#xD;
&#xD;
          -  Subjects who consume citrus fruits and juices, (in particular grapefruits and Seville&#xD;
             oranges, sour or bitter oranges), or products containing St. John's wort (Hypericum&#xD;
             perforatum) are not allowed 7 days prior to dose administration&#xD;
&#xD;
          -  Excessive physical activity or exercise (such as organized sports) during the trial&#xD;
             period&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

